tradingkey.logo

ImmuCell Corp

ICCC
View Detailed Chart

5.960USD

+0.310+5.49%
Close 09/19, 16:00ETQuotes delayed by 15 min
53.91MMarket Cap
30.60P/E TTM

ImmuCell Corp

5.960

+0.310+5.49%
Intraday
1m
30m
1h
D
W
M
D

Today

+5.49%

5 Days

+0.68%

1 Month

+1.02%

6 Months

+23.65%

Year to Date

+15.73%

1 Year

+64.19%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered undervalued,and institutional recognition is very high. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
103 / 175
Overall Ranking
340 / 4720
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing Immediate Immunity against each of the three causes of calf scours (E. coli, coronavirus, and rotavirus).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 42.68% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 26.49M.
Overvalued
The company’s latest PE is 29.01, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 4.25M shares, decreasing 2.03% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 308.70K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.54.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing Immediate Immunity against each of the three causes of calf scours (E. coli, coronavirus, and rotavirus).
Ticker SymbolICCC
CompanyImmuCell Corp
CEOMr. Michael F. Brigham
Websitehttps://immucell.com/
KeyAI